PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Frequently asked questions
What sector does PepGen Ltd (PEPG) operate in?
PepGen Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is PepGen Ltd (PEPG) current stock price?
As of the latest data, PepGen Ltd stock price is $2.54, with a previous close of $2.49. PepGen Ltd gained $0.05 in the last trading session, representing a 1.81% increase.
What is PepGen Ltd (PEPG) current market capitalization?
PepGen Ltd market cap is approximately 175.34 million.
What is PepGen Ltd (PEPG) Earnings Per Share (EPS)?
The trailing EPS is -$1.01, and the forward EPS is -$1.06.
What is PepGen Ltd (PEPG) EBITDA?
PepGen Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -16.61 million.
Does PepGen Ltd (PEPG) pay dividends?
No. PepGen Ltd does not pay a dividend.
When is PepGen Ltd (PEPG) next earnings report?
PepGen Ltd is expected to release its next earnings report on September 30, 2026.
What is PepGen Ltd (PEPG) beta (volatility) score?
PepGen Ltd has a beta of 2.007, indicating very high volatility compared to the market.